Baruffi, Ricardo L.R.Mauri, A. L. [UNESP]Petersen, C. G. [UNESP]Felipe, V.Martins, A. M CCornicelli, J.Cavagna, M.Oliveira, J. B AFranco, J. G.2014-05-272014-05-272007-01-01Reproductive BioMedicine Online, v. 14, n. 1, p. 14-25, 2007.1472-6483http://hdl.handle.net/11449/69439This study aims to compare the efficacy of recombinant LH (rLH) supplementation for ovarian stimulation in gonadotrophin-releasing hormone-antagonist protocol for IVF/intracytoplasmic sperm injection cycles. Search strategies included online surveys of databases. The fixed effects model was used for odds ratio (OR) and effect size (weighted mean difference, WMD). Five trials fulfilled the inclusion criteria. When the meta-analysis was carried out, advantages were observed for the LH supplementation protocol with respect to higher serum oestradiol concentrations on the day of human chorionic gonadotrophin administration (P < 0.0001; WMD: 514, 95% CI 368, 660) and higher number of mature oocytes (P = 0.0098; WMD: 0.88, 95% CI 0.21, 1.54). However, these differences were not observed in the total amount of recombinant FSH (rFSH) administered, days of stimulation, number of oocytes retrieved, the clinical pregnancy rate per oocyte retrieval, the implantation rate and miscarriage rate. This result demonstrates that the association of rLH with rFSH may prevent any decrease in oestradiol after antagonist administration and that a significantly higher number of mature oocytes was available for laboratory work. Nevertheless, it failed to show any statistically significant difference in clinically significant end-points in IVF (implantation and pregnancy rates). Additional randomized controlled trials are needed to confirm these results further. © 2007 Published by Reproductive Healthcare Ltd.14-25engGnRH antagonistOvarian stimulationRecombinant FSHRecombinant LHcetrorelixchorionic gonadotropinestradiolgonadorelin antagonistrecombinant follitropinrecombinant luteinizing hormonecell countclinical protocolclinical trialcombination chemotherapycontrolled clinical trialcontrolled studydata basedrug dose increasedrug dose reductiondrug efficacydrug withdrawaleffect sizeestradiol blood levelevidence based medicinefertilization in vitrohormonal regulationhumanintracytoplasmic sperm injectionlow drug dosemeta analysismonotherapymultiple cycle treatmentoocyte maturationovulation inductionpregnancy raterandomized controlled trialrisk assessmentsingle drug dosespontaneous abortionsystematic reviewEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGonadotropin-Releasing HormoneHumansLuteinizing HormoneOvulation InductionPregnancyPregnancy RateRandomized Controlled TrialsRecombinant ProteinsSperm Injections, IntracytoplasmicTreatment OutcomeArtigo10.1016/S1472-6483(10)60758-4WOS:000243506300006Acesso restrito2-s2.0-33846503177